Abatacept + Placebo

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Scleroderma, Diffuse

Conditions

Scleroderma, Diffuse, Scleroderma, Systemic

Trial Timeline

Nov 1, 2008 → Jun 1, 2011

NCT ID

NCT00442611

About Abatacept + Placebo

Abatacept + Placebo is a phase 1/2 stage product being developed by Bristol Myers Squibb for Scleroderma, Diffuse. The current trial status is completed. This product is registered under clinical trial identifier NCT00442611. Target conditions include Scleroderma, Diffuse, Scleroderma, Systemic.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02108860	Phase 3	Completed	Apr 25, 2015	Dec 20, 2023	Granulomatosis With Polyangiitis (Wegener's)
NCT02778906	Phase 3	Completed	Nov 1, 2014	Dec 1, 2019	Arthralgia
NCT02161406	Phase 2	Completed	Sep 1, 2014	Oct 17, 2018	Diffuse Cutaneous Systemic Sclerosis
NCT02232880	Phase 2	Terminated	Aug 1, 2014	Jun 1, 2015	Hypertension
NCT01860976	Phase 3	Completed	Jun 17, 2013	Jun 30, 2020	Psoriatic Arthritis
NCT00442611	Phase 1/2	Completed	Nov 1, 2008	Jun 1, 2011	Scleroderma, Diffuse
NCT00784459	Phase 2	Completed	Oct 1, 2008	Feb 1, 2012	Atopic Asthma
NCT00533897	Phase 3	Completed	Nov 1, 2007	Feb 1, 2014	Rheumatoid Arthritis
NCT00534313	Phase 2	Terminated	Nov 1, 2007	May 1, 2011	Psoriatic Arthritis
NCT00420199	Phase 3	Completed	May 1, 2007	May 1, 2010	Active Rheumatoid Arthritis
NCT00345748	Phase 2	Completed	Jun 1, 2006	Nov 1, 2007	Rheumatoid Arthritis
NCT00124449	Phase 2	Completed	Feb 1, 2005	Apr 1, 2008	Arthritis, Rheumatoid

Competing Products

15 competing products in Scleroderma, Diffuse

See all competitors

Product	Company	Stage	Hype Score
IVA337 + Placebo	Inventiva	Phase 2	47
Cuprimine (penicillamine)	Merck	Pre-clinical	23
rapcabtagene autoleucel + rituximab	Novartis	Phase 2	52
STI571	Novartis	Phase 2	52
Imatinib mesylate	Novartis	Phase 2	52
imatinib mesylate	Novartis	Phase 2	52
Mycophenolate mofetil	Roche	Pre-clinical	23
Mycophenolate mofetil + Cyclophosphamide + Placebo	Roche	Phase 2	52
Fludarabine + Cyclophosphamide + Thymoglobulin	Amgen	Phase 1	32
BMS-986020	Bristol Myers Squibb	Phase 2	51
dasatinib	Bristol Myers Squibb	Phase 1/2	40
AVID200	Bristol Myers Squibb	Phase 1	32
Rilonacept	Regeneron Pharmaceuticals	Phase 1/2	40
Riociguat + Placebo	Bayer	Phase 2	49
Riociguat (Adempas, BAY63-2521) + Placebo	Bayer	Phase 2	49

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved